IP Library Patent Application 17498834
Patent Application
App. No. 17/498,834

IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/498,834
Abstract

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Claims (10)

1 . A pharmaceutical composition, comprising

a synthetic peptide which is IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25); and an enhancer selected from the group consisting of: transforming growth factor beta (TGF-β), rapamycin, fingolimod (FTY720), and a sphingosine kinase 1 inhibitor.

2 . A pharmaceutical composition, comprising

a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25); and an enhancer selected from the group consisting of: high molecular weight hyaluronic acid, IL-2, IL-5, all-trans retinoic acid, anti-CD3, anti-CD28, vitamin D3, dexamethasone, IL-10, idolamine-2,3-dioxygenase, cholera toxin B subunit, ovalbumin, Flt2L, sirolimus, anti-thymocyte globulin, and CTLA-4/Ig.

3 . A method of treating a patient suffering from an autoimmune disease, comprising

administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).

4 . A method of treating a patient suffering from an immune disease of the eye, comprising

administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).

5 . A method of treating a patient suffering from dysfunctional regulatory T-cells, comprising

administering to said patient a synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2) or VTVDVTNNTEKTVKK (SEQ ID NO: 3) or IFKKISRDKSVTIYL (SEQ ID NO: 5) or VKGKKVYVTLTCAFR (SEQ ID NO: 6) or YGQEDVDVIGLTFRR (SEQ ID NO: 7) or LPLLANNRERRGIAL (SEQ ID NO: 8) or DTNLASSTIIKEGID (SEQ ID NO: 9) or VTVDVNSSEK (SEQ ID NO: 14) or GESISVNVHIQNNSNKTVKK (SEQ ID NO: 20) or GEPITVTVSVTN (SEQ ID NO: 22) or IPVTIDVTDN (SEQ ID NO: 25).

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →